U.K. cost watchdogs nix Dendreon's Provenge; GSK's Slaoui joins IAVI board;

> The U.K.'s cost watchdogs have deemed Dendreon's ($DNDN) cancer vaccine Provenge too expensive for coverage on England's National Health Service. Report

> GlaxoSmithKline ($GSK) Global Vaccines Chairman Moncef Slaoui has joined the board of directors of the International AIDS Vaccine Initiative (IAVI). Release

> Sanofi Pasteur is planning a large-scale renovation project that will include construction of a new quality control building, set to begin early this year. Report

> San Diego, CA-based biotech Polynoma has launched a Phase III trial of its melanoma vaccine candidate. More

And Finally... Influenza vaccination may protect against Guillain-Barre syndrome, a new study suggests. More (reg. req.)

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.